The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSpectra (di/ S) Regulatory News (SPSC)

Share Price Information for Spectra (di/ S) (SPSC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 260.00
Bid: 220.00
Ask: 300.00
Change: 0.00 (0.00%)
Spread: 80.00 (36.364%)
Open: 260.00
High: 260.00
Low: 260.00
Prev. Close: 260.00
SPSC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results for Six Months Ended 30 June 2022

12 Sep 2022 07:00

RNS Number : 0189Z
Spectra Systems Corporation
12 September 2022
 

 

Spectra Systems Corporation

Interim Results for the Six Months Ended 30 June 2022

 

 

Spectra Systems Corporation (the "Company"), a leader in machine-readable high speed banknote authentication, brand protection technologies, and gaming security software, is pleased to announce its interim results for the six months ended 30 June 2022.

 

 

Financial highlights:

 

· Revenue of $9,265k (2021: $8,023k) up 15%

 

· Adjusted EBITDA1 up 8% at $3,818k (2021: $3,522k)

 

· Adjusted PBTA1 up 8% to $3,669k (2021: $3,383k)

 

· Adjusted earnings2 per share down 7% to US $6.2 cents (2021: US $6.7 cents)

 

· Cash generated from operations of $7,245k (2021: $4,464k) 

 

· Annual 2021 dividend of US$0.11 per share ($5,004k in aggregate) paid in June 2022

 

· Strong, debt-free balance sheet, with cash3 of $17,961k (2021: $12,851k) at 30 June

 

· Buy-back of 350,000 shares in the period

 

1 Before stock compensation expense and excludes noncontrolling interest

2 Before amortization and stock compensation expense, excludes noncontrolling interest and fewer remaining tax credits

3 Does not include $500,000 (2021: $1,099k) of restricted cash and investments

 

 

Operational highlights:

· Increased total central bank sensor revenue with additional contract enhancements (amendments) for increased sensor testing and more flexibility with sorter integration

 

· Began a funded development to mitigate supply chain impacts in raw materials with a central bank customer

 

· Successfully completed a second gravure test of TruBrandTM with a major cigarette supplier in China

 

· Executed an agreement with a strategic partner for dairy and transit licences in India

 

 

· Rollout of our FusionTM machine readable polymer substrate at the Banknote 2022 conference

 

 

· Sale of our first Banknote Disinfection System to an Asian central bank

· Achieved a nearly three-fold increase in sales revenue for K-cup optical materials through a second large customer

 

 

· Provided polymer substrate samples to a Middle Eastern central bank with a second set being delivered in H2 of 2022

 

 

· Expanded the lottery business into Canada with a new contract award and renewed a long-term US customer contract

 

 

Commenting on the results, Nabil Lawandy, Chief Executive Officer, said:

 

"The Company's first half revenues and earnings are up substantially from the six months ended June 30, 2021 and in line with the Board's upward revised expectations for H1. Our cash position has greatly increased due to sensor development prepayments, additional sales, and release of part of the restricted cash associated with the last sensor deployment.

We have obtained new business from a long-standing central bank customer which supports our position as the technology leader for the highest-level security requirements. During 2022 the Company has been granted additional contract enhancements (amendments) which have increased the value of the sensor development work to $14.4MM for this customer. Based on the current program timeline, we continue to plan around a late 2024 delivery for the first order of sensors with the total value of all units after delivery being approximately $50m with additional ongoing service revenues.

Spectra Systems, with our proven track record of developing solutions for our customers in record time, has capitalized on the environment that was created by the Covid-19 pandemic. While other companies complained that they could not source materials and electronics components we took the approach of solving the problems for our customers. Our efforts on this front have been two-fold:

· We have initiated a program with a central bank customer to shore up the supply chain for taggants by manufacturing in-house a previously commercially sourced chemical. This effort will result in development payments and an ongoing price increase for our high-performance consumables; and

 

· We developed the world's largest capacity, and shortest process time, banknote disinfection machine and sold our first unit to an Asian central bank. 

On the optical materials front, we have significantly grown revenue from K-cup printers and have had successful TruBrandTM gravure print trials with a second major cigarette supplier in China. In addition, we are commencing a new testing program with a large Japanese label supplier, and have executed a supply agreement with a strategic partner in India for dairy products and transit vouchers.

Finally, our gaming software operation continues to make steady progress towards completion of our new Integrity product which will result in a more compelling sales proposition as well as a reduction in support costs going forward. Completion of the new Premier Integrity product is expected to be in late 2023.

"The Board therefore believes that the Company is on track to achieve record earnings and meet market expectations for the full year."

 

Spectra Systems Corporation

Dr. Nabil Lawandy, Chief Executive Officer

Tel: +1 (0)401 274 4700

 

WH Ireland Limited (Nominated Adviser and Joint Broker)

Chris Fielding (Head of Corporate Finance)

 

Allenby Capital Limited (Joint Broker)

Nick Naylor/James Reeve (Corporate Finance)

Amrit Nahal (Sales and Corporate Broking) 

Tel: +44 (0)20 7220 1650

 

 

Tel: +44 (0)20 3328 5665

 

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the “UK MAR”) which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company’s obligations under Article 17 of the UK MAR. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

Chief Executive Officer's statement

 

Introduction

Already in 2022, we have upgraded market expectations twice and are now significantly outperforming H1 2021 results while our cash position is the highest in the company's history and nearly at the IPO closing levels.

Revenue was up 15% at $9,265k (2021: $8,023k) for the first half of the year. The increased revenues in the first half are derived principally from pre-production development contracts as well as larger demand for our materials to meet increased banknote demands of one of our existing central bank customers.

 

As a result of the increased revenue, adjusted EBITDA (before stock compensation expense) for the half year increased 8%, to $3,818k compared to the prior year of $3,552k.

 

Having generated cash from operations of $7,245k (2021: $4,464k), cash at the period end amounted to $17,961k (2021: $12,851k), excluding $500,000 of restricted cash and investments (2021: $1,099k). This is notwithstanding $5,004k paid to shareholders during June in the form of the Company's dividend of $0.11 per share and $570k used for buying back 350,000 shares. 

 

 

 

 

Review of Operations

 

 

Physical and Software Authentication Business

 

The Authentication Systems business generated revenue of $8,565k (2021: $7,103k) and Adjusted EBITDA of $3,878k (2021: $3,470k). Authentication Systems revenues are driven by sales of covert materials and their associated equipment and service, optical and security phosphour materials and licence payments from our licensee. The increased revenue is due to a combination of sizable materials orders and increased sensor development funding from our long-standing central bank customer, as well as increased optical materials sales. The increase in development funding as well as the central bank lowering our performance bond has also significantly increased our cash position. We continue to move forward with this central bank towards the delivery of the first sensors in late 2024.

 

Through our vertically integrated manufacturing we have been able to produce high quality conducting and opacified polymer substrate for evaluation by central banks, ink suppliers and printing organizations. We have produced a large number of custom designed sheets for a Middle Eastern central bank print trial which has resulted in a request for a second set of substrate sheets to be delivered in 2022 for further evaluation. In addition, the Company has formed a close working relationship with the largest commercial printer of polymer banknotes and is developing a house note which will incorporate both our FusionTM machine readable security as well as their newest public security feature. The Directors understand that the result of this joint development will produce polymer banknotes of the highest quality for a joint marketing effort.

 

We are increasing our sales and marketing efforts for FusionTM as well as our suite of banknote products and are taking full advantage of the availability of experienced individuals, as well as equipment, which have become available since the closing of the Portals Overton facility.

 

With the TruBrandTM authentication product having been successfully introduced into the Chinese tobacco market with over 6 million packs with our smartphone authentication in retail stores in 2019, we have completed two successful gravure tests with another large supplier of cigarettes in China. Although these successful trials resulted in a binding agreement with this supplier, progress has been stalled by recent political tensions between the USA and China. We continue to expand our search for new TruBrandTM customers outside of China, including a major Japanese printer, a partnership with a company in India bidding on authentication of both dairy products as well as transit certificates, and tax stamps in a European country.

 

In addition, we are in an evaluation phase aimed at increasing the customer base for the other authentication technology we acquired several years ago with a printer for a well-respected French luxury brand to help protect their products sold in China. The Company also expects to fill orders in H2 for over a hundred handheld readers for use in authentication tax stamps produced by a large banknote printer.

 

Our K-cup materials business has grown significantly after a new customer began purchasing our products in H2 of 2021. Revenues for the full year 2022 are expected to be nearly three times higher than 2021. Through an internal development effort, we have achieved a significant cost reduction for manufacturing the covert materials, further boosting our margins on this product.

 

On the software security side of the Company's business, the Secure Transactions Group, formed around two gaming technology acquisitions made in 2012, generated an Adjusted EBITDA of ($60K) (2021: $112k) on revenue of $700k (2021: $920k). The H1 results are in line with expectations as we continue development of a new software platform with heavy staffing costs depressing EBITDA.  While this development continues, we are focusing on the online lottery sector which grew during the pandemic through a partnership with NextGen Lotteries.

 

 

 

Banknote Cleaning and Disinfection Business

 

We have sold our first Banknote Disinfection System (BDS) for use by an Asian central bank. The unit will be installed in H2 and the terms included a 30% up-front payment as well as a follow-on service agreement. As this system is scalable from 250,000 notes to over five million notes in a single cycle of one hour, we have the ability to accommodate a large spread of potential customer requirements. With this first unit sold, we are ramping up our sales and marketing process to other central banks as well as the casino industry.

 

 

Solaris BioSciences Investment Asset

 

In December 2020, the Company made an investment in Solaris BioSciences, whose results are consolidated by the Company. The technology is entirely optical and has three major target opportunities which are all focused on extremely low volumes of biofluids: blood plasma viscosity for inflammation, milk viscosity for dysphagia in newborns, and protein markers for cancer survivors to track metastasis. The combined market opportunity for a two-minute, microliter sample volume (pinprick) tests are believed to be well over 1 billion per annum in consumables.

 

During H1, Solaris BioSciences Holdings was formed as a UK company and has obtained EIS status with HMRC. Solaris has also engaged W H Ireland to undertake a private equity financing which is currently underway.

 

Corporate Governance

Spectra Systems is an AIM listed company and has always tried to abide by best practices as advised by both our bankers as well as our shareholders. Recently ISS has issued certain recommendations regarding board composition, committee assignments, and option grants.

Our board has comprised the same Directors since our listing with the exception of the addition of Mr. Jeremy Fry (UK based) who replaced Mr. Martin Jaskel after his untimely passing away. In order to add a new dimension to the board, we are actively recruiting a new board member. We have identified a candidate and are working through the regulatory approval process.

With the addition of this new board member, Dr. Nabil Lawandy will be able to exit the Audit Committee assignment as there will be a suitable replacement to share the burden of committee assignments.

With regards to Director option grants, the Company has adopted a new policy which will allow new Directors to receive a one-time option grant upon joining the board of directors. Going forward, no Directors will be issued new options beyond the ones received at joining the board. This is a compromise position relative to USA standards and ISS recommendations that Directors hold no options.

 

Strategy

The Company's strategy for increasing revenue and earnings continues to be focused on selling more products to existing customers as well as opening new sales channels for the full spectrum of our product offering. We have had very good success in upselling existing central bank customers and commercially exploiting supply chain and pandemic related issues as part of our strategy. Examples of these successes are the expansion of sensor capabilities for exotic counterfeits, the development and first sale of a banknote disinfection machine, and the commencement of a program with our customer to deal with supply chain issues now and going forward.

Our strategy for growing our newest and potentially transformative technology for polymer banknotes is based on validation, followed by commemorative banknote contract and then a full banknote denomination contract. The validation is focused on three major stakeholders in the polymer banknote industry: the ink manufacturers, the commercial printers, and the state printworks. Our primary targets are central banks which are currently using paper substrates and are contemplating a transition to polymer as well as central banks who have decided not to use polymer for higher denominations due to security concerns.

With regards to our optical materials and brand authentication products, we continue to propose to both central banks and overt security suppliers the concept of upgrading such features to incorporate public and machine-readable security. The strategy behind this approach is based around partnering with current contract holders who can benefit from our technology and materials to upsell their existing customers. This approach is being implemented with TruBrandTM as well as with our gaming software business where we have partnered with online lottery suppliers to mutually benefit from the combination of capabilities at a compelling price point.

Finally, we are exploring possible mergers and acquisitions which can immediately open doors to implement our upselling strategy and expand our customer base. The exploration of such opportunities has always been in the background but is now becoming more viable at larger scales as we expect to have significant cash resources through the successful delivery of the major central bank sensor contract.

 

Prospects

The Company continues to have a multitude of new short-term and long-term prospects. The short-term opportunities are expected in the 2022-2024 period and the long-term opportunities are expected in the 2025-2030-time frame. 

The near-term opportunities are:

A new supply chain impact mitigation contract with a central bank

Increase in taggant pricing with a central bank customer

Completion of sensor development and revenue recognition of the remaining $7.7m of sensor development payments

New online Quality Control system contract

First sensor shipments to a central bank

TruBrandTM revenue reaching $1m per annum levels

Sale of additional Banknote Disinfection Systems

Increased sales of our newest phosphour products

Expansion of our gaming software business in Canada and other non-USA customers and in the online lottery market

 

 The longer-term opportunities are:

A commemorative note series using our Fusion polymer substrate

Supply of upgraded sensors worth up to $50MM in hardware to a central bank customer

Supply of FusionTM polymer substrate and sensors to a central bank for a banknote denomination

Significantly increased adoption of covert authentication materials by a current or new central bank customer

 

The combination of these prospects, both short and long-term, has positioned the Company to continue its revenue and earnings growth over the coming years. We continue to develop cutting edge technologies to remain the technology leader in the authentication industry and to offer our shareholders growth through innovation for both new and existing customers.

 

Nabil M. Lawandy

Chief Executive Officer

September 12, 2022Consolidated statements of income

for the half year ended 30 June 2022

 

 

 

 

Half Year

 

Half Year

 

Full Year

 

 

to 30 Jun 2022

 

to 30 Jun 2021

 

to 31 Dec 2021

 

 

Unaudited

 

Unaudited

 

Audited

 

Note

USD '000

 

USD '000

 

USD '000

Revenues

Product

$ 5,488

$ 4,607

$ 9,281

Service

2,907

2,548

5,524

License and royalty

870

868

1,787

Total revenues

9,265

8,023

16,592

Cost of sales

3,145

2,578

6,069

Gross profit

6,120

5,445

10,523

Operating expenses

Research and development

837

755

1,399

General and administrative

1,481

1,433

2,743

Sales and marketing

478

230

471

Total operating expenses

2,796

2,418

4,613

Operating profit

3,324

3,027

5,910

Interest and other income

8

29

40

Loss on sale of equipment

-

(19)

  (19)

Foreign currency gain(loss)

3

(3)

12

Profit before taxes

3,335

3,034

5,943

Income tax expense

707

157

878

Net income

2,628

2,877

5,065

Net loss attributable to noncontrolling interest

 

22

 

71

 

98

Net income attributable to Spectra Systems Corporation

 

$ 2,650

 

$ 2,948

 

$ 5,163

Earnings per share

Basic

$ 0.06

$ 0.06

$ 0.11

Diluted

$ 0.06

$ 0.06

$ 0.11

All of the Group's operations are continuing

 

Consolidated statements of comprehensive income

for the half year ended 30 June 2022

 

 

Half Year

 

Half Year

 

Full Year

 

to 30 Jun 2022

 

to 30 Jun 2021

 

to 31 Dec 2021

 

Unaudited

 

Unaudited

 

Audited

 

USD '000

 

USD '000

 

USD '000

 

 

 

 

 

 

Net income

$ 2,628

 

$ 2,877

 

$ 5,065

 

Other comprehensive income (loss)

 

 

 

 

 

Unrealized gain (loss) on currency exchange

 

1

 

(6)

 

10

Reclassification for realized (gain) loss in net income

 

(3)

 

3

 

(12)

Total other comprehensive

loss

 

(2)

 

(3)

 

(2)

Comprehensive income

2,626

2,874

5,063

 

Net loss attributable to noncontrolling interest

 

22

 

71

 

98

 

Comprehensive income attributable to Spectra Systems Corporation

$ 2,648

$ 2,945

$ 5,161

 

 

 

Consolidated balance sheets

as of 30 June 2022

 

 

As of

 

As of

 

As of

 

30 Jun 2022

 

30 Jun 2021

 

31 Dec 2021

 

Unaudited

 

Unaudited

 

Audited

 

USD '000

 

USD '000

 

USD '000

Current assets

Cash and cash equivalents

$ 17,961

$ 12,851

$ 16,775

Trade receivables, net of allowance

1,384

1,870

2,242

Unbilled and other receivables

527

478

630

Inventory

2,192

2,737

1,944

Prepaid expenses

1,272

327

299

Total current assets

23,336

18,263

21,889

 

Non-current assets

Property, plant and equipment, net

1,617

1,557

1,439

Operating lease right of use assets, net

828

1,045

972

Intangible assets, net

7,057

7,178

7,161

Restricted cash and investments

500

1,099

500

Deferred tax assets

530

1,400

1,080

Other assets

105

118

111

Total non-current assets

10,637

12,397

11,263

 

Total assets

$ 33,973

$ 30,660

$ 33,152

Current liabilities

Accounts payable

$ 664

$ 681

$ 490

Accrued expenses and other liabilities

465

446

512

Operating lease liabilities, short term

289

267

286

Taxes payable

49

28

262

Deferred revenue

1,898

2,066

2,184

Total current liabilities

3,365

3,488

3,734

 

Non-current liabilities

Operating lease liabilities, long term

595

827

739

Deferred revenue

4,968

650

758

Total non-current liabilities

5,563

1,477

1,497

 

Total liabilities

8,928

4,965

5,231

Stockholders' equity

Common stock

451

453

453

Additional paid in capital - common stock

53,336

53,795

53,833

Accumulated other comprehensive loss

(138)

(137)

(137)

Accumulated deficit

(29,224)

(29,085)

(26,870)

Total Spectra Systems Corporation stockholders' equity

 

24,425

 

25,026

 

27,279

Noncontrolling interest

620

669

642

Total stockholders' equity

25,045

25,695

27,921

Total liabilities and stockholders' equity

$ 33,973

$ 30,660

$ 33,152

 

 

Consolidated statements of cash flows

for the half year ended 30 June 2022

 

 

 

Half Year

 

Half Year

 

Full Year

 

to 30 Jun 2022

 

to 30 Jun 2021

 

to 31 Dec 2021

 

Unaudited

 

Unaudited

 

Audited

 

USD '000

 

USD '000

 

USD '000

Cash flows from operating activities

 

 

 

 

 

Net income

$ 2,628

$ 2,877

$ 5,065

Adjustments to reconcile net income to net cash provided by operating activities

Depreciation and amortization

418

398

831

Stock based compensation expense

65

33

71

Lease amortization expense

142

137

274

Deferred taxes

550

-

320

Provision for excess and obsolete inventory

-

-

494

Loss on sale of equipment

-

19

19

Changes in operating assets and liabilities

Accounts receivables

861

719

346

Unbilled and other receivables

102

(1)

(153)

Inventory

(248)

57

356

Prepaid expenses

(974)

(53)

(25)

Accounts payable

175

146

(44)

Operating leases

(140)

(132)

(265)

Accrued expenses and other liabilities

(262)

(230)

71

Deferred revenue

3,928

494

724

Net cash provided by operating activities

7,245

4,464

8,084

 

Cash flows from investing activities

Restricted cash and investments

-

-

599

Payment of patent and trademark costs

(147)

(223)

(471)

Proceeds from sale of equipment

-

36

36

Purchases of property, plant and equipment

(338)

(32)

(76)

Net cash provided by (used in) investing activities

(485)

(219)

88

 

Cash flows from financing activities

Dividends paid

(5,004)

(4,302)

(4,302)

Repurchase of shares

(570)

(1,170)

(1,170)

Proceeds from exercise of stock options

6

37

38

Net cash used in financing activities

(5,568)

(5,435)

(5,434)

Effect of exchange rate on cash and cash equivalents

 

(6)

 

3

 

(1)

Net increase(decrease) in cash and cash equivalents

(1,186)

(1,187)

2,737

Cash and cash equivalents, beginning of period

 

16,775

 

14,038

 

14,038

Cash and cash equivalents, end of period

$ 17,961

$ 12,851

$ 16,775

 

 

Notes to financial information

 

1. Basis of preparation

 

This report was approved by the Directors on the 9th of September 2022.

 

This financial information has been prepared using the recognition and measurement principles of US Generally Accepted Accounting Principles (GAAP). The Group has not elected to apply IAS 34 Interim Financial Reporting.

 

The principal accounting policies used in preparing the interim results are those the Company expects to apply in its financial statements for the year ending 31 December 2022 and are unchanged from those disclosed in the Company's Annual Report for the year ended 31 December 2021.

 

The results for the half year are unaudited. The financial information for the year ended 31 December 2021 does not constitute the full statutory accounts for that period. The Annual Report and financial statements for the year ended 31 December 2021 have been filed with the Registrar of Companies. The Independent Auditors' Report on the financial statements for the year ended 31 December 2021 was unmodified and did not draw attention to any matters by way of emphasis.

 

2. Earnings per share

 

The calculation of basic earnings per share is based on the net income divided by the weighted average number of common shares outstanding. Diluted earnings per share is calculated by considering the dilutive impact of common stock equivalents under the treasury stock method as if they were converted into common stock as of the beginning of the period or as of the date of grant, if later. Excluded from the calculation of diluted earnings per common share for the six months ended June 30, 2022 and the year ended December 31, 2021 were 159,845 and 125,425 shares related to stock options, respectively, because their exercise prices would render them anti-dilutive. For the six months ended June 30, 2021,118,740 were excluded from the calculation of diluted earnings per common share. The following table shows the calculation of basic and diluted earnings per common share.

 

Half Year

Half Year

Full Year

to 30 Jun 2022

to 30 Jun 2021

to 31 Dec 2021

Numerator:

Net income

$ 2,650,000

$ 2,948,000

$ 5,162,830

Denominator:

Weighted average common shares

45,569,258

45,415,199

45,353,550

Effect of dilutive securities:

Stock Options

2,233,298

2,662,613

2,385,480

Diluted weighted average common shares

 

47,802,556

 

48,077,812

 

47,739,030

Earnings per common share:

Basic:

$ 0.06

$ 0.06

$ 0.11

Diluted:

$ 0.06

$ 0.06

$ 0.11

 

 

3. Investment in affiliates and other entities

 

During the course of business, the Company enters into various types of investment arrangements. The Company determines whether such investments involve variable interest entities (VIEs). If the entity is determined to be a VIE, then management determines if the Company is the primary beneficiary of the entity and whether or not consolidation of the VIE is required. The primary beneficiary consolidating the VIE must normally have both (i) the power to direct the activities of a VIE that most significantly affect the VIE's economic performance and (ii) the obligation to absorb losses of the VIE or the right to receive benefits from the VIE, in either case that could potentially be significant to the VIE. When the Company is deemed to be the primary beneficiary, the VIE is consolidated and the other party's equity interest in the VIE is accounted for as a noncontrolling interest.

On December 10, 2020, the Company invested $702,000 in Solaris BioSciences ("Solaris") and increased its equity interest from 4.79% to 48.65% on an as converted basis. A noncontrolling interest is attributable to the 51.35% of Solaris not owned by the Company. Prior to the investment, the Chief Executive Officer of Spectra owned 84.54% of Solaris which declined to 46.01% after the transaction. As part of the transaction, the Company committed to provide $100,000 of services at cost to Solaris, of which $93,558 were provided during the six months ended June 30, 2021. In addition, the Company will provide nominal accounting support to Solaris and allow Solaris use of optical table space and facilities at Spectra. In accordance with Delaware law, the transaction was (a) unanimously approved by all three of Spectra's non-executive Directors and (b) specially approved by a majority-in-interest of the disinterested stockholders of Solaris. In addition, going forward Spectra's shares in Solaris will be voted as directed by Spectra's non-executive Directors. The Chief Executive Officer of Solaris is also the Chief Executive Officer of Spectra.

The Company has concluded that Solaris is a VIE and the Company is the primary beneficiary. The Company has consolidated the accounts of Solaris as of December 10, 2020. The aggregate carrying value of Solaris' assets and liabilities after elimination of any intercompany transactions and balances in the consolidated balance sheets were as follows:

 

 

As of

 

As of

 

As of

 

30 Jun 2022

 

30 Jun 2021

 

31 Dec 2021

 

Unaudited

 

Unaudited

 

Audited

 

USD '000

 

USD '000

 

USD '000

Assets

Cash

$ 101

$ 218

$ 150

Property, plant and equipment, net

7

8

8

Intangible assets, net

56

8

40

Total Assets

164

234

197

Liabilities

Accounts payable

-

10

21

Accrued expenses and other liabilities

-

8

-

Total liabilities

$ -

$ 18

$ 21

 

 

4. Copies of this statement are available to the public on the Company's website at http://www.spsy.com.

 

 

 

Appendix - Reconciliation of Non-GAAP measures

 

The Company publishes certain additional information in a non-statutory format in order to provide readers with an increased insight into the underlying performance of the business. Reconciliations to the GAAP measures are shown in the following tables:

 

 

Half Year

 

Half Year

 

Full Year

 

to 30 Jun 2022

 

to 30 Jun 2021

 

to 31 Dec 2021

 

Unaudited

 

Unaudited

 

Unaudited

 

USD '000

 

USD '000

 

USD '000

 

Adjusted earnings before interest, taxes,

depreciation and amortization (EBITDA)

Operating profit

$ 3,324

$ 3,027

$ 5,910

Depreciation

159

146

307

Amortization

257

252

524

Stock compensation

65

33

71

Operating loss - noncontrolling interest

22

71

101

Stock compensation - noncontrolling interest

(10)

(7)

(17)

Adjusted EBITDA

$ 3,817

$ 3,522

$ 6,896

 

Adjusted profit before taxes and

amortization (PBTA)

Profit before taxes

$ 3,335

$ 3,034

$ 5,943

Amortization

257

252

524

Stock compensation

65

33

71

Operating loss - noncontrolling interest

22

71

101

Stock compensation - noncontrolling interest

(10)

(7)

(17)

Adjusted PBTA

$ 3,669

$ 3,383

$ 6,622

 

Adjusted earnings per share

Adjusted PBTA

$ 3,669

$ 3,383

$ 6,622

Income tax expense

(707)

(157)

(878)

Adjusted earnings

$ 2,962

$ 3,226

$ 5,744

 

Diluted weighted average common shares

47,802,556

48,077,812

47,739,030

 

Adjusted earnings per share

$ 0.062

$ 0.067

$ 0.120

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FLFEDAIILLIF
Date   Source Headline
27th Mar 20247:00 amRNSAudited results for 12 months ended 31 Dec 2023
11th Jan 20247:00 amRNSExercise of Options and Director/PDMR Shareholding
28th Dec 20237:00 amRNSExercise of Options
21st Dec 202312:15 pmRNSCompletion of Acquisition
15th Dec 20234:35 pmRNSExercise of Options and transfer of shares
4th Dec 20237:00 amRNSAcquisition of Cartor Holdings Limited
6th Nov 20234:43 pmRNSTR-1
12th Oct 20237:00 amRNSLargest Central Bank Consumables Order
25th Sep 20237:00 amRNSInterim Results for Six Months Ended 30 June 2023
7th Jul 20236:01 pmRNSRemoval of Regulation S restrictions from shares
26th Jun 20233:22 pmRNSAnnual General Meeting Lack of Quorum
30th May 20237:00 amRNSAppointment of Chief Financial Officer
25th Apr 20237:00 amRNSAdditional Sensor Services Contract Amendment
24th Apr 20237:00 amRNSResignation of Chief Financial Officer
19th Apr 20237:05 amRNSRemoval of Reg S restrictions from common stock
6th Apr 20237:00 amRNSExercise of Options
31st Mar 20235:14 pmRNSRemoval of Reg S restrictions from shares
21st Mar 202311:44 amRNSDividend Record Date
20th Mar 20237:00 amRNSAudited results for year ended 31 December 2022
16th Mar 20234:35 pmRNSExercise of Options
6th Mar 202310:39 amRNSRemoval of Reg S restrictions from common stock
11th Oct 20226:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20227:00 amRNSContract Amendment to a Central Bank
21st Sep 20227:00 amRNSExercise of Options
12th Sep 20227:05 amRNSAppointment of Non-Executive Director
12th Sep 20227:00 amRNSInterim Results for Six Months Ended 30 June 2022
16th Aug 20227:00 amRNSFirst Banknote Disinfection System Sold
15th Aug 20227:00 amRNSNew Central Bank Contract Amendment
28th Jul 20227:00 amRNSShare Buy-Back
1st Jul 20222:31 pmRNSShare Buy-Back
28th Jun 20227:00 amRNSShare Buy-Back
15th Jun 20227:00 amRNSAdditional Central Bank Development Revenues
14th Jun 20227:00 amRNSAppointment of Chief Financial Officer
13th Jun 20227:00 amRNSAnnual General Meeting Update
25th May 20227:00 amRNSExercise of Options and Director/PDMR Shareholding
20th May 20228:44 amRNSRemoval of Regulation S restrictions from shares
20th May 20228:41 amRNSResignation of Chief Financial Officer
3rd May 20227:00 amRNSPosting of Annual Report & Notice of AGM
6th Apr 20221:36 pmRNSRemoval of Reg S restrictions from common stock
28th Mar 20227:00 amRNSGrant of Share Options
21st Mar 20227:00 amRNSResults twelve months ended 31 December 2021
24th Jan 20227:00 amRNSNew contract awards
21st Jan 20227:00 amRNSExercise of Options
6th Dec 20217:00 amRNSNew K-cup Orders in Q4 Exceed Expectations
2nd Nov 20213:37 pmRNSExercise of Options
25th Oct 20214:18 pmRNSRemoval of Regulation S restrictions
11th Oct 20217:00 amRNSLarge Central Bank Order
13th Sep 202110:27 amRNSHolding(s) in Company
25th Aug 202111:23 amRNSRemoval of Regulation S restrictions
21st Jul 20217:00 amRNSBanknote cleaning system also deactivates Covid-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.